Pharmaceutical compound
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.694 |
Chemical and physical data | |
Formula | C18H17ClN2O3 |
Molar mass | 344.80 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Arfendazam (INN) is a drug which is a benzodiazepine derivative. Arfendazam is a 1,5-benzodiazepine, with the nitrogen atoms located at positions 1 and 5 of the diazepine ring, and so is most closely related to other 1,5-benzodiazepines such as clobazam.
Arfendazam has sedative and anxiolytic effects similar to those produced by other benzodiazepine derivatives, but is a partial agonist at GABAA receptors, so the sedative effects are relatively mild and it produces muscle relaxant effects only at very high doses.
Arfendazam produces an active metabolite lofendazam, which is thought to be responsible for part of its effects.
See also
References
- "International Nonproprietary Names for Pharmaceutical Substances. Proposed International Nonproprietary Names (Prop. INN): List 39. Supplement to WHO Chronicle" (PDF). World Health Organization. March 1978. p. 3. Retrieved 4 December 2015.
- Mueller E (January 1985). "Benzodiazepine receptor interactions of arfendazam, a novel 1, 5-benzodiazepine". Pharmacopsychiatry. 18 (1): 10–1. doi:10.1055/s-2007-1017288. S2CID 144951247.
- Müller WE, Groh B, Bub O (July 1986). "In vitro and in vivo studies of the mechanism of action of arfendazam, a novel 1, 5-benzodiazepine". Pharmacopsychiatry. 19 (4): 314–315. doi:10.1055/s-2007-1017251. S2CID 143919337.
- Adrien J, Albani F, Baruzzi A, Berger M, Bixler EO, Borbeley AA, Dikeos DG, Drucker-Colin R, Montero RF, Hishikawa Y, Inoue S (December 2012). The Pharmacology of Sleep. Springer Science & Business Media. ISBN 978-3-540-58961-7.
Anxiolytics (N05B) | |
---|---|
5-HT1ARTooltip 5-HT1A receptor agonists | |
GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators |
|
Hypnotics | |
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Antipsychotics | |
Sympatholytics (Antiadrenergics) |
|
Others | |
|
Benzodiazepines | |
---|---|
1,4-Benzodiazepines |
|
1,5-Benzodiazepines | |
2,3-Benzodiazepines* | |
Triazolobenzodiazepines | |
Imidazobenzodiazepines | |
Oxazolobenzodiazepines | |
Thienodiazepines | |
Thienotriazolodiazepines | |
Thienobenzodiazepines* | |
Pyridodiazepines | |
Pyridotriazolodiazepines | |
Pyrazolodiazepines | |
Pyrrolodiazepines | |
Tetrahydroisoquinobenzodiazepines | |
Pyrrolobenzodiazepines* | |
Benzodiazepine prodrugs | |
* atypical activity profile (not GABAA receptor ligands) |
GABAA receptor positive modulators | |
---|---|
Alcohols | |
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This sedative-related article is a stub. You can help Misplaced Pages by expanding it. |